<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01854593</url>
  </required_header>
  <id_info>
    <org_study_id>CCT-NAPN-23170</org_study_id>
    <nct_id>NCT01854593</nct_id>
  </id_info>
  <brief_title>Prospective Randomized Controlled Study of Intravitreal Injection of Bevacizumab for Proliferative Diabetic Retinopathy</brief_title>
  <official_title>Prospective Randomized Controlled Study of Intravitreal Injection of 0.16 mg Bevacizumab One Day Before Surgery for Proliferative Diabetic Retinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nihon University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nihon University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We hypothesized that to reduce the adverse effects of intravitreal bevacizumab on ocular
      tissue and whole body, intravitreal injection of a low concentration of bevacizumab and
      conducting vitrectomy shortly after the injection is useful. In the present prospective,
      double-masked, randomized, controlled study, we aimed to verify the usefulness of
      intravitreal injection of 0.16 mg/0.05 ml bevacizumab one day before conducting vitrectomy
      for PDR.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Early postoperative hemorrhage in proliferative diabetic retinopathy (PDR) patients is a
      major complication. Intravitreal injection of anti-vascular endothelial growth factor (VEGF)
      has reported to reduce vitreous hemorrhage. Recently, numerous reports have shown the
      efficacy of reducing neovascularization activity before vitrectomy by preoperative
      intravitreal injection of anti-VEGF agents. When intravitreal bevacizumab (IVB) injection is
      used as an adjunct therapy, a shortterm effect is needed. Because it is reported some adverse
      events caused by bevacizumab injection. Hattori et al reported intravitreal injection of 0.16
      mg/0.05 ml bevacizumab in PDR patients marked blockage of intravitreal VEGF concentrations in
      the pilot study. The purpose of this study is to evaluate low dose of intravitreal
      bevacizumab as a preoperative adjunct therapy reduce the postoperative vitreous hemorrhage.
      This study involves PDR patients who underwent vitrectomy between May 2012 and August 2013 at
      Surugadai Hospital of Nihon University. The risks to participants are accompanied by the
      intravitreal injection of bevacizumab (especially the possibility of endophthalmitis and
      thromboembolic events).

      Between June 2012 and August 2013, one investigator (AM) randomized PDR patients with an
      indication for primary 25-gauge vitrectomy into a sham group and an IVB group. One day after
      injection, three surgeons except AM conducted the surgeries. Vitreous samples were collected
      at the start of surgery, and intraoperative and postoperative complications were evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reoperation</measure>
    <time_frame>1 month</time_frame>
    <description>Vitreoretinal reoperation due to recurrent vitreous hemorrhage.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intra Operative Hemorrhage</measure>
    <time_frame>End of the surgery.</time_frame>
    <description>Calculate the number of coagulators for the intra operative hemorrhage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Vitreous Hemorrhage.</measure>
    <time_frame>1 month</time_frame>
    <description>Postoperative vitreous hemorrhage that is permitted within 4 weeks after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular Endothelial Growth Factor Concentration in Vitreous</measure>
    <time_frame>Start of surgery.</time_frame>
    <description>Vascular endothelial growth factor concentration in vitreous at the start of vitrectomy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endolaser Photocoagulation</measure>
    <time_frame>End of surgery.</time_frame>
    <description>Number of intraoperative endolaser photocoagulation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Iatrogenic Retinal Tears</measure>
    <time_frame>End of surgery.</time_frame>
    <description>The number of participants who had intraoperative iatrogenic retinal tears.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical Time</measure>
    <time_frame>End of surgery.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Best Corrected Visual Acuity</measure>
    <time_frame>1 mouth after surgery.</time_frame>
    <description>Best corrected visual acuity was measured using the Landolt ring chart, and the result was converted to logMAR notation for analysis.
The minimum of the scale is 2.0 and the maximum of the scale is -0.3. The higher values represent a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Corrected Visual Acuity Change</measure>
    <time_frame>1 month</time_frame>
    <description>Best corrected visual acuity change was calculated by postoperative logMAR visual acuity minus preoperative logMAR visual acuity.
The higher values represent a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Neovascular Glaucoma</measure>
    <time_frame>Within 1 month after the surgery.</time_frame>
    <description>The number of participants with progressive or persistent neovascular glaucoma after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elevated Intraocular Pressure</measure>
    <time_frame>Within 1 month after the surgery.</time_frame>
    <description>The number of participants with elevated intraocular pressure after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gas Tamponade</measure>
    <time_frame>End of surgery.</time_frame>
    <description>The number of participants with gas tamponade at the end of the surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Silicon Oil Tamponade</measure>
    <time_frame>End of surgery.</time_frame>
    <description>The number of participants with silicon oil tamponade at the end of the surgery.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Proliferative Diabetic Retinopathy</condition>
  <condition>Diabetic Traction Retinal Detachment</condition>
  <condition>Vitreous Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Bevacizumab injection and vitrectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.16 mg/0.05 ml bevacizumab intravitreal injection one day before vitrectomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham injection and vitrectomy</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham injection one day before vitrectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>0.16 mg/0.05 ml bevacizumab (single injection on 1 day before operation)</description>
    <arm_group_label>Bevacizumab injection and vitrectomy</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Vitrectomy</intervention_name>
    <description>vitrectomy of 25 gauge system.</description>
    <arm_group_label>Bevacizumab injection and vitrectomy</arm_group_label>
    <arm_group_label>Sham injection and vitrectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham injection</intervention_name>
    <description>Sham injection one day before vitrectomy</description>
    <arm_group_label>Sham injection and vitrectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of Proliferative Diabetic Retinopathy (PDR)

          -  Indicated for vitrectomy

        Exclusion Criteria:

          -  History of intraocular surgery, intravitreal injection of drugs or sub-Tenon injection
             of steroids or retinal photocoagulation within 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ayumu Manabe</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Surugadai Nihon University Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>101-8309</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2013</study_first_submitted>
  <study_first_submitted_qc>May 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2013</study_first_posted>
  <results_first_submitted>December 29, 2013</results_first_submitted>
  <results_first_submitted_qc>June 11, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 14, 2014</results_first_posted>
  <last_update_submitted>June 11, 2014</last_update_submitted>
  <last_update_submitted_qc>June 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nihon University</investigator_affiliation>
    <investigator_full_name>Ayumu Manabe</investigator_full_name>
    <investigator_title>Ayumu Manabe</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Retinal Detachment</mesh_term>
    <mesh_term>Vitreous Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bevacizumab and Vitrectomy</title>
          <description>0.16mg/0.05ml bevacizumab intravitreal injection one day before surgery and vitrectomy.
Bevacizumab: 0.16mg/0.05ml bevacizumab (single injection on 1 day before operation)
Vitrectomy: vitrectomy of 25 gauge system.</description>
        </group>
        <group group_id="P2">
          <title>Sham Injection and Vitrectomy</title>
          <description>Sham injection one day before operation and vitrectomy.
Sham injection: Sham injection one day before vitrectomy
Vitrectomy: vitrectomy of 25 gauge system.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bevacizumab and Vitrectomy</title>
          <description>0.16 mg/0.05 ml bevacizumab intravitreal injection one day before surgery and vitrectomy.
Bevacizumab: 0.16 mg/0.05 ml bevacizumab (single injection on 1 day before operation)
Vitrectomy: vitrectomy of 25 gauge system.</description>
        </group>
        <group group_id="B2">
          <title>Sham Injection and Vitrectomy</title>
          <description>Sham injection one day before operation and vitrectomy.
Sham injection: Sham injection one day before vitrectomy
Vitrectomy: vitrectomy of 25 gauge system.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="34"/>
            <count group_id="B3" value="66"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.9" spread="11.8"/>
                    <measurement group_id="B2" value="59.2" spread="12.9"/>
                    <measurement group_id="B3" value="59.6" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Preoperative best corrected visual acuity</title>
          <description>Preoperative best corrected visual acuity</description>
          <units>LogMAR</units>
          <param>Log Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.09" spread="0.60"/>
                    <measurement group_id="B2" value="1.14" spread="0.58"/>
                    <measurement group_id="B3" value="1.11" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Intra Ocular Pressure</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.3" spread="2.69"/>
                    <measurement group_id="B2" value="14.6" spread="3.42"/>
                    <measurement group_id="B3" value="15.0" spread="3.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hypertension</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hyperlipidemia</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c</title>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.0" spread="1.7"/>
                    <measurement group_id="B2" value="7.6" spread="2.0"/>
                    <measurement group_id="B3" value="7.8" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Use of anticoagulants</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lens status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>phakic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pseudophakic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Persistent vitreous hemorrhage</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous panretinal photocoagulation</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Incomplete</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>preoperative Iris neovascularization or neovascular glaucoma</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Intra Operative Hemorrhage</title>
        <description>Calculate the number of coagulators for the intra operative hemorrhage.</description>
        <time_frame>End of the surgery.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab and Vitrectomy</title>
            <description>0.16mg/0.05ml bevacizumab intravitreal injection one day before surgery and vitrectomy.
Bevacizumab: 0.16mg/0.05ml bevacizumab (single injection on 1 day before operation)
Vitrectomy: vitrectomy of 25 gauge system.</description>
          </group>
          <group group_id="O2">
            <title>Sham Injection and Vitrectomy</title>
            <description>Sham injection one day before operation and vitrectomy.
Vitrectomy: vitrectomy of 25 gauge system.
Sham injection: Sham injection one day before vitrectomy</description>
          </group>
        </group_list>
        <measure>
          <title>Intra Operative Hemorrhage</title>
          <description>Calculate the number of coagulators for the intra operative hemorrhage.</description>
          <units>coagulators</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63" spread="1.0"/>
                    <measurement group_id="O2" value="1.3" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.025</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Vitreous Hemorrhage.</title>
        <description>Postoperative vitreous hemorrhage that is permitted within 4 weeks after surgery.</description>
        <time_frame>1 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab and Vitrectomy</title>
            <description>0.16mg/0.05ml bevacizumab intravitreal injection one day before surgery and vitrectomy.
Bevacizumab: 0.16mg/0.05ml bevacizumab (single injection on 1 day before operation)
Vitrectomy: vitrectomy of 25 gauge system.</description>
          </group>
          <group group_id="O2">
            <title>Sham Injection and Vitrectomy</title>
            <description>Sham injection one day before operation and vitrectomy.
Vitrectomy: vitrectomy of 25 gauge system.
Sham injection: Sham injection one day before vitrectomy</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Vitreous Hemorrhage.</title>
          <description>Postoperative vitreous hemorrhage that is permitted within 4 weeks after surgery.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Reoperation</title>
        <description>Vitreoretinal reoperation due to recurrent vitreous hemorrhage.</description>
        <time_frame>1 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab and Vitrectomy</title>
            <description>0.16mg/0.05ml bevacizumab intravitreal injection one day before surgery and vitrectomy.
Bevacizumab: 0.16mg/0.05ml bevacizumab (single injection on 1 day before operation)
Vitrectomy: vitrectomy of 25 gauge system.</description>
          </group>
          <group group_id="O2">
            <title>Sham Injection and Vitrectomy</title>
            <description>Sham injection one day before operation and vitrectomy.
Vitrectomy: vitrectomy of 25 gauge system.
Sham injection: Sham injection one day before vitrectomy</description>
          </group>
        </group_list>
        <measure>
          <title>Reoperation</title>
          <description>Vitreoretinal reoperation due to recurrent vitreous hemorrhage.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.033</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vascular Endothelial Growth Factor Concentration in Vitreous</title>
        <description>Vascular endothelial growth factor concentration in vitreous at the start of vitrectomy.</description>
        <time_frame>Start of surgery.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab and Vitrectomy</title>
            <description>0.16mg/0.05ml bevacizumab intravitreal injection one day before surgery and vitrectomy.
Bevacizumab: 0.16mg/0.05ml bevacizumab (single injection on 1 day before operation)
Vitrectomy: vitrectomy of 25 gauge system.</description>
          </group>
          <group group_id="O2">
            <title>Sham Injection and Vitrectomy</title>
            <description>Sham injection one day before operation and vitrectomy.
Vitrectomy: vitrectomy of 25 gauge system.
Sham injection: Sham injection one day before vitrectomy</description>
          </group>
        </group_list>
        <measure>
          <title>Vascular Endothelial Growth Factor Concentration in Vitreous</title>
          <description>Vascular endothelial growth factor concentration in vitreous at the start of vitrectomy.</description>
          <units>Î¼g/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" spread="13.6"/>
                    <measurement group_id="O2" value="1315" spread="1153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endolaser Photocoagulation</title>
        <description>Number of intraoperative endolaser photocoagulation.</description>
        <time_frame>End of surgery.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab and Vitrectomy</title>
            <description>0.16mg/0.05ml bevacizumab intravitreal injection one day before surgery and vitrectomy.
Bevacizumab: 0.16mg/0.05ml bevacizumab (single injection on 1 day before operation)
Vitrectomy: vitrectomy of 25 gauge system.</description>
          </group>
          <group group_id="O2">
            <title>Sham Injection and Vitrectomy</title>
            <description>Sham injection one day before operation and vitrectomy.
Vitrectomy: vitrectomy of 25 gauge system.
Sham injection: Sham injection one day before vitrectomy</description>
          </group>
        </group_list>
        <measure>
          <title>Endolaser Photocoagulation</title>
          <description>Number of intraoperative endolaser photocoagulation.</description>
          <units>photocoagulation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1260" spread="686"/>
                    <measurement group_id="O2" value="1335" spread="663"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.667</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Iatrogenic Retinal Tears</title>
        <description>The number of participants who had intraoperative iatrogenic retinal tears.</description>
        <time_frame>End of surgery.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab and Vitrectomy</title>
            <description>0.16mg/0.05ml bevacizumab intravitreal injection one day before surgery and vitrectomy.
Bevacizumab: 0.16mg/0.05ml bevacizumab (single injection on 1 day before operation)
Vitrectomy: vitrectomy of 25 gauge system.</description>
          </group>
          <group group_id="O2">
            <title>Sham Injection and Vitrectomy</title>
            <description>Sham injection one day before operation and vitrectomy.
Vitrectomy: vitrectomy of 25 gauge system.
Sham injection: Sham injection one day before vitrectomy</description>
          </group>
        </group_list>
        <measure>
          <title>Iatrogenic Retinal Tears</title>
          <description>The number of participants who had intraoperative iatrogenic retinal tears.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.593</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Surgical Time</title>
        <time_frame>End of surgery.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab and Vitrectomy</title>
            <description>0.16mg/0.05ml bevacizumab intravitreal injection one day before surgery and vitrectomy.
Bevacizumab: 0.16mg/0.05ml bevacizumab (single injection on 1 day before operation)
Vitrectomy: vitrectomy of 25 gauge system.</description>
          </group>
          <group group_id="O2">
            <title>Sham Injection and Vitrectomy</title>
            <description>Sham injection one day before operation and vitrectomy.
Vitrectomy: vitrectomy of 25 gauge system.
Sham injection: Sham injection one day before vitrectomy</description>
          </group>
        </group_list>
        <measure>
          <title>Surgical Time</title>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49" spread="20"/>
                    <measurement group_id="O2" value="56" spread="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.298</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Best Corrected Visual Acuity</title>
        <description>Best corrected visual acuity was measured using the Landolt ring chart, and the result was converted to logMAR notation for analysis.
The minimum of the scale is 2.0 and the maximum of the scale is -0.3. The higher values represent a worse outcome.</description>
        <time_frame>1 mouth after surgery.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab and Vitrectomy</title>
            <description>0.16mg/0.05ml bevacizumab intravitreal injection one day before surgery and vitrectomy.
Bevacizumab: 0.16mg/0.05ml bevacizumab (single injection on 1 day before operation)
Vitrectomy: vitrectomy of 25 gauge system.</description>
          </group>
          <group group_id="O2">
            <title>Sham Injection and Vitrectomy</title>
            <description>Sham injection one day before operation and vitrectomy.
Vitrectomy: vitrectomy of 25 gauge system.
Sham injection: Sham injection one day before vitrectomy</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Best Corrected Visual Acuity</title>
          <description>Best corrected visual acuity was measured using the Landolt ring chart, and the result was converted to logMAR notation for analysis.
The minimum of the scale is 2.0 and the maximum of the scale is -0.3. The higher values represent a worse outcome.</description>
          <units>LogMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46" spread="0.54"/>
                    <measurement group_id="O2" value="0.43" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.929</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Best Corrected Visual Acuity Change</title>
        <description>Best corrected visual acuity change was calculated by postoperative logMAR visual acuity minus preoperative logMAR visual acuity.
The higher values represent a worse outcome.</description>
        <time_frame>1 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab and Vitrectomy</title>
            <description>0.16mg/0.05ml bevacizumab intravitreal injection one day before surgery and vitrectomy.
Bevacizumab: 0.16mg/0.05ml bevacizumab (single injection on 1 day before operation)
Vitrectomy: vitrectomy of 25 gauge system.</description>
          </group>
          <group group_id="O2">
            <title>Sham Injection and Vitrectomy</title>
            <description>Sham injection one day before operation and vitrectomy.
Vitrectomy: vitrectomy of 25 gauge system.
Sham injection: Sham injection one day before vitrectomy</description>
          </group>
        </group_list>
        <measure>
          <title>Best Corrected Visual Acuity Change</title>
          <description>Best corrected visual acuity change was calculated by postoperative logMAR visual acuity minus preoperative logMAR visual acuity.
The higher values represent a worse outcome.</description>
          <units>LogMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.63" spread="0.61"/>
                    <measurement group_id="O2" value="-0.73" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.445</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Neovascular Glaucoma</title>
        <description>The number of participants with progressive or persistent neovascular glaucoma after surgery.</description>
        <time_frame>Within 1 month after the surgery.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab Injection and Vitrectomy</title>
            <description>0.16mg/0.05ml bevacizumab intravitreal injection one day before surgery and vitrectomy.
Bevacizumab: 0.16mg/0.05ml bevacizumab (single injection on 1 day before operation)
Vitrectomy: vitrectomy of 25 gauge system.</description>
          </group>
          <group group_id="O2">
            <title>Sham Injection and Vitrectomy</title>
            <description>Sham injection one day before operation and vitrectomy.
Vitrectomy: vitrectomy of 25 gauge system.
Sham injection: Sham injection one day before vitrectomy</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Neovascular Glaucoma</title>
          <description>The number of participants with progressive or persistent neovascular glaucoma after surgery.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.131</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Elevated Intraocular Pressure</title>
        <description>The number of participants with elevated intraocular pressure after surgery.</description>
        <time_frame>Within 1 month after the surgery.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab Injection and Vitrectomy</title>
            <description>0.16mg/0.05ml bevacizumab intravitreal injection one day before surgery and vitrectomy.
Bevacizumab: 0.16mg/0.05ml bevacizumab (single injection on 1 day before operation)
Vitrectomy: vitrectomy of 25 gauge system.</description>
          </group>
          <group group_id="O2">
            <title>Sham Injection and Vitrectomy</title>
            <description>Sham injection one day before operation and vitrectomy.
Vitrectomy: vitrectomy of 25 gauge system.
Sham injection: Sham injection one day before vitrectomy</description>
          </group>
        </group_list>
        <measure>
          <title>Elevated Intraocular Pressure</title>
          <description>The number of participants with elevated intraocular pressure after surgery.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.149</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gas Tamponade</title>
        <description>The number of participants with gas tamponade at the end of the surgery.</description>
        <time_frame>End of surgery.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab Injection and Vitrectomy</title>
            <description>0.16mg/0.05ml bevacizumab intravitreal injection one day before surgery and vitrectomy.
Bevacizumab: 0.16mg/0.05ml bevacizumab (single injection on 1 day before operation)
Vitrectomy: vitrectomy of 25 gauge system.</description>
          </group>
          <group group_id="O2">
            <title>Sham Injection and Vitrectomy</title>
            <description>Sham injection one day before operation and vitrectomy.
Vitrectomy: vitrectomy of 25 gauge system.
Sham injection: Sham injection one day before vitrectomy</description>
          </group>
        </group_list>
        <measure>
          <title>Gas Tamponade</title>
          <description>The number of participants with gas tamponade at the end of the surgery.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.670</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Silicon Oil Tamponade</title>
        <description>The number of participants with silicon oil tamponade at the end of the surgery.</description>
        <time_frame>End of surgery.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab Injection and Vitrectomy</title>
            <description>0.16mg/0.05ml bevacizumab intravitreal injection one day before surgery and vitrectomy.
Bevacizumab: 0.16mg/0.05ml bevacizumab (single injection on 1 day before operation)
Vitrectomy: vitrectomy of 25 gauge system.</description>
          </group>
          <group group_id="O2">
            <title>Sham Injection and Vitrectomy</title>
            <description>Sham injection one day before operation and vitrectomy.
Vitrectomy: vitrectomy of 25 gauge system.
Sham injection: Sham injection one day before vitrectomy</description>
          </group>
        </group_list>
        <measure>
          <title>Silicon Oil Tamponade</title>
          <description>The number of participants with silicon oil tamponade at the end of the surgery.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.378</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 month</time_frame>
      <desc>1 month after vitrectomy.</desc>
      <group_list>
        <group group_id="E1">
          <title>Bevacizumab and Vitrectomy</title>
          <description>0.16mg/0.05ml bevacizumab intravitreal injection one day before surgery and vitrectomy.
Bevacizumab: 0.16mg/0.05ml bevacizumab (single injection on 1 day before operation)
Vitrectomy: vitrectomy of 25 gauge system.</description>
        </group>
        <group group_id="E2">
          <title>Sham Injection and Vitrectomy</title>
          <description>Sham injection one day before operation and vitrectomy.
Vitrectomy: vitrectomy of 25 gauge system.
Sham injection: Sham injection one day before vitrectomy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ayumu Manabe</name_or_title>
      <organization>Department of Ophthalmology, Surugadai Hospital of Nihon University</organization>
      <phone>+81-3-3293-1711 ext 429</phone>
      <email>ayumu.m76@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

